Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Ed Arce maintains Ardelyx (NASDAQ:ARDX) with a Buy and raises the price target from $10 to $11.
Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and raises the price target from $10 to $12.
Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $11 price target.
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30...
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovati...
HC Wainwright & Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:ARDX) with a Buy and maintains $10 price target.
Ardelyx challenges CMS in a lawsuit over Medicare's inclusion of Xphozah in bundled payments, affecting kidney disease drug...
Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $11 price target.
